MedTrace Logo

Altered Brain GABA and Glutamate in Restless Legs Syndrome

NCT01109537 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2015-01-07

No results posted yet for this study

Summary

The purpose of the study is to understand the brain chemistry of people with Restless Legs Syndrome (RLS). The primary hypothesis is that patients with RLS will have reduced GABA levels in their Thalamus and elevated Glutamate levels in their Anterior Cingulate Cortex. The study will use MRS imaging to examine the regional levels of these neurochemicals, GABA and Glutamate, in the brain.

Conditions

  • Restless Legs Syndrome

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • John W Winkelman, MD, PhD · Sleep Health Centers, Brigham and Women's Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01109537 on ClinicalTrials.gov